Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × avelumab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Breast 1

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Ovarian Neoplasms 5 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Merkel Cell 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Neoplasm, Residual 1 Mesothelioma, Malignant 1 Melanoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1

Interventions

palbociclib 2 Trastuzumab 2 Capecitabine 2 trastuzumab deruxtecan 1 tetrathiomolybdate 1 sacituzumab govitecan 1 pembrolizumab 1 niraparib 1 inavolisib 1 giredestrant 1 eribulin 1 avelumab 1 atezolizumab 1 abemaciclib 1 Zymosan 1 Radiotherapy 1 Letrozole 1 Immunotherapy 1 Hydroxychloroquine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡